GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

GlaxoSmithKline has announced more data making the case for its multiple myeloma antibody-drug conjugate GSK2857916, confirming that almost two thirds of patients responded to the drug after an ...

A: Avastin; Ag: Antigen; mAb: Monoclonal antibody; MM: Multiple myeloma ... conjugates are a novel strategy aiming to minimize side effects of chemotherapy and specifically deliver cytotoxic drugs ...

The Orphan Drug designation was supported by preclinical research and preliminary data from the dose escalation/expansion phase 1/2 trial.

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

There are also a host of other multiple myeloma drugs in the pharma pipeline – there are high hopes for drugs such as GSK’s belantamab mafodotin, an antibody-drug conjugate that produced ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

But over time, the disease is able to change and become resistant to the drugs most often used to fight it. When multiple myeloma comes back after treatment, that’s called a relapse. When ...

As pharmaceutical companies embrace antibody-drug conjugates (ADCs) as a way to treat cancer, drug services providers are ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...